Sara Saberi

7.1k total citations · 2 hit papers
69 papers, 1.4k citations indexed

About

Sara Saberi is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Surgery. According to data from OpenAlex, Sara Saberi has authored 69 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Cardiology and Cardiovascular Medicine, 12 papers in Epidemiology and 8 papers in Surgery. Recurrent topics in Sara Saberi's work include Cardiomyopathy and Myosin Studies (45 papers), Cardiovascular Function and Risk Factors (31 papers) and Cardiovascular Effects of Exercise (16 papers). Sara Saberi is often cited by papers focused on Cardiomyopathy and Myosin Studies (45 papers), Cardiovascular Function and Risk Factors (31 papers) and Cardiovascular Effects of Exercise (16 papers). Sara Saberi collaborates with scholars based in United States, Italy and United Kingdom. Sara Saberi's co-authors include Sharlene M. Day, Iacopo Olivotto, Amy J. Sehnert, Euan A. Ashley, Perry Elliott, Matthew T. Wheeler, Daniel Jacoby, Adam Helms, Carolyn Y. Ho and Suwen Kumar and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

Sara Saberi

59 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2021 127 citations John A. Spertus, Perry Elliott et al. profile →
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

2024 34 citations Florian Rader, Artur Oręziak et al. JACC Heart Failure profile →

Peers

Countries citing papers authored by Sara Saberi

Since Specialization

Citations

This map shows the geographic impact of Sara Saberi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Saberi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Saberi more than expected).

Fields of papers citing papers by Sara Saberi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Saberi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Saberi. The network helps show where Sara Saberi may publish in the future.

Co-authorship network of co-authors of Sara Saberi

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Saberi. A scholar is included among the top collaborators of Sara Saberi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Saberi. Sara Saberi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis 2025 ·Journal of the American Heart Association ·(unknown), Ahmad Masri, Sara Saberi, Martin S. Maron, (unknown), (unknown), (unknown), Roberto Barriales‐Villa, Anjali Owens, Gregory D. Lewis	0
2	Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients to Mavacamten Based on Sex 2025 ·JACC Heart Failure ·Milind Y. Desai, Sara Saberi, Jeffrey B. Geske, Andrew Z. Wang, Paul Cremer, David Fermin, (unknown), Neal K. Lakdawala, Albree Tower‐Rader, Srihari S. Naidu, Kathy Lampl, Anjali Owens	2
3	Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: An analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials 2025 ·Heart Rhythm ·(unknown), (unknown), (unknown), Caroline Coats, Theodore P. Abraham, Michael E. Nassif, Roberto Barriales‐Villa, Sara Saberi, Stephen B. Heitner, Daniel Jacoby, Stuart Kupfer, Fady I. Malik, Tyrell Simkins, (unknown), Ahmad Masri	0
4	Atrial Fibrillation in Hypertrophic Cardiomyopathy 2024 ·SHILAP Revista de lepidopterología ·(unknown), Sara Saberi, Timothy C. Wong, Antonis Pantazis, Anjali Owens, Alexander Leunig, Chikezie Alvarez, Florian Rader	9
5	Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response 2024 ·Journal of the American Heart Association ·Anjali Owens, Milind Y. Desai, Matthew T. Wheeler, (unknown), (unknown), Amy J. Sehnert, Sara Saberi	6
6	Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM 2024 ·Circulation ·Milind Y. Desai, Kathy Wolski, Anjali Owens, Jeffrey B. Geske, Sara Saberi, Andrew Wang, Mark V. Sherrid, Paul Cremer, Neal K. Lakdawala, Albree Tower‐Rader, David Fermin, Srihari S. Naidu, Nicholas G. Smedira, Hartzell V. Schaff, (unknown), (unknown), Kathy Lampl, Amy J. Sehnert, Steven E. Nissen, (unknown)	14
7	Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy breakdown → 2024 ·JACC Heart Failure ·Florian Rader, Artur Oręziak, Lubna Choudhury, Sara Saberi, David Fermin, Matthew T. Wheeler, Theodore P. Abraham, Pablo García‐Pavía, Donna R. Zwas, Ahmad Masri, Anjali Owens, Sheila M. Hegde, Tim Seidler, Shawna Fox, Ganesh Balaratnam, Amy J. Sehnert, Iacopo Olivotto	34
8	Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence‐based practice resource of the National Society of Genetic Counselors 2024 ·Journal of Genetic Counseling ·Erin M. Miller, Emily Brown, Susan Christian, Melissa Kelly, (unknown), Sara Saberi, Christina Rigelsky, Jodie Ingles	1
9	Qualitative interview study of patient-reported symptoms, impacts and treatment goals of patients with obstructive hypertrophic cardiomyopathy 2024 ·BMJ Open ·Supriya Shore, (unknown), Katherine Kosa, Sheri Fehnel, Lisa Salberg, Michael Butzner, Stephen B. Heitner, Daniel Jacoby, Sara Saberi	0
10	Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy 2023 ·European Heart Journal ·Eugene Braunwald, Sara Saberi, Theodore P. Abraham, Perry Elliott, Iacopo Olivotto	53
11	Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension 2023 ·JACC Heart Failure ·Andrew Wang, John A. Spertus, Daniel Wojdyla, Theodore P. Abraham, (unknown), Anjali Owens, Sara Saberi, Sharon Cresci, Amy J. Sehnert, Neal K. Lakdawala	7
12	Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM 2023 ·Circulation ·Sharon Cresci, Richard G. Bach, Sara Saberi, Anjali Owens, John A. Spertus, Sheila M. Hegde, Neal K. Lakdawala, (unknown), Daniel Wojdyla, Amy J. Sehnert, Andrew Wang	11
13	Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks 2022 ·Circulation ·Milind Y. Desai, Anjali Owens, Jeffrey B. Geske, Kathy Wolski, Sara Saberi, Andrew Wang, Mark V. Sherrid, Paul Cremer, Srihari S. Naidu, Nicholas G. Smedira, Hartzell V. Schaff, Ellen McErlean, Christina Sewell, Aarthi Balasubramanyam, Kathy Lampl, Amy J. Sehnert, Steven E. Nissen	53
14	THE EFFECT OF MAVACAMTEN ON CARDIOPULMONARY EXERCISE TESTING PERFORMANCE OF PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN EXPLORER-HCM 2022 ·Journal of the American College of Cardiology ·(unknown), Iacopo Olivotto, Perry Elliott, Sara Saberi, Anjali Owens, Mathew S. Maurer, Ahmad Masri, Amy J. Sehnert, Jay M. Edelberg, Wanying Li, Victoria Florea, Rajeev Malhotra, Andrew Wang, Artur Oręziak, Daniel Jacoby, Jonathan Myers	2
15	Cardiopulmonary Exercise Testing Following Open Repair for a Proximal Thoracic Aortic Aneurysm or Dissection 2019 ·Journal of Cardiopulmonary Rehabilitation and Prevention ·Whitney Hornsby, Elizabeth L. Norton, (unknown), Sara Saberi, Xiaoting Wu, Cheri L. McGowan, Robert D. Brook, Lee W. Jones, Cristen J. Willer, Himanshu J. Patel, Kim A. Eagle, Carl J. Lavie, Melvyn Rubenfire, Bo Yang	20
16	Dynamics of leukocyte telomere length in pregnant women living with HIV, and HIV-negative pregnant women: A longitudinal observational study 2019 ·PLoS ONE ·Sara Saberi, Steve E. Kalloger, (unknown), Beheroze Sattha, Evelyn J. Maan, (unknown), Deborah Money, Hélène C. F. Côté, (unknown)	8
17	Genetic testing impacts the utility of prospective familial screening in hypertrophic cardiomyopathy through identification of a nonfamilial subgroup 2017 ·Genetics in Medicine ·(unknown), Patricia Arscott, Maryann Concannon, Sara Saberi, Sharlene M. Day, Beverly M. Yashar, Adam Helms	33
18	Optimization of a Relative Telomere Length Assay by Monochromatic Multiplex Real-Time Quantitative PCR on the LightCycler 480 2016 ·Journal of Molecular Diagnostics ·(unknown), Sara Saberi, (unknown), Kyle R. Hukezalie, (unknown), Beheroze Sattha, Hélène C. F. Côté	32
19	Sports and Exercise in Athletes with Hypertrophic Cardiomyopathy 2015 ·Clinics in Sports Medicine ·Craig Alpert, Sharlene M. Day, Sara Saberi	13
20	The Antiprogestins RU486 and ZK98299 Affect Follicle-Stimulating Hormone Secretion Differentially on Estrus, but not on Proestrus* 1997 ·Endocrinology ·S J Ringstrom, Márta Szabó, Signe M. Kilen, Sara Saberi, Kerry L. Knox, Neena B. Schwartz	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact